Web Analytics

3 Latest Announced Rounds

  • $1,000,000
    Pre-Seed

    3 Investors

    Technology, Information and Internet
    Jun 27th, 2025
  • $12,000,000
    Series A
    Mental Health Care
    Jun 27th, 2025
  • $8,000,000
    Seed

    2 Investors

    Software Development
    Jun 27th, 2025
$1,962.72M Raised in 58 Funding Rounds in the past 7 Days - View All

Funding Round Profile

Allay Therapeutics

start up
United States - San Jose, California
  • 06/06/2025
  • Series D
  • $57,500,000

Allay Therapeutics is pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation for patients and physicians.

We believe an era of stalled innovation for pain management is over. From San Francisco to Singapore, our team has a passion for solving medical challenges that could benefit millions. We pursue our mission with the energy of a dynamic, global team of entrepreneurs, scientists, clinicians and innovators.


Related People

Adam GridleyFounder

Adam Gridley United States - Greater Boston

Executive Officer with over 25 years of transactional and operational experience in venture capital backed startups to mature fully integrated organizations in the biotechnology, medical device, and pharmaceutical industries. Completed strategic transactions & shareholder exits totaling >$600M, venture capital/royalty fundraising totaling >$200M and public offerings (IPO and secondary) totaling >$250M. Established strategy as part of executive management teams, growing revenues to >$300M, hired and led senior (C-Level to VP level) leadership teams, and secured multiple FDA PMA, NDA, and 510(k) approvals.

Functional leadership in and P&L responsibility for market development, international sales distribution, M&A/business development, R&D, regulatory & clinical affairs, manufacturing & logistics, patent & legal affairs, quality operations, facilities, finance, and information technology.

Areas of expertise include: Organization Transformation, R&D, Strategic Planning, Integrating Acquisitions and Products, Business Development, Investor & Shareholder Relations, Board of Directors and KOL Engagement, Crisis Management & Restructuring, Product Development, FDA & Global Regulatory Approvals, Lean & Continuous Improvement, Financial Analysis, and P&L/Cost Management.